Multidrug resistant tuberculosis conversion rate after initiation on standardised short regimen: Retrospective study

CURRENT STATUS: UNDER REVIEW

Nomawethu Somfongo
University of Fort Hare

Wiseman Mupindu
University of Fort Hare

nozuko mangi nmangi@ufh.ac.za
Taylor University
Corresponding Author

DOI: 10.21203/rs.2.23851/v1

SUBJECT AREAS
Health Policy

KEYWORDS
Short regimen, multi-drug resistant TB, rifampicin resistant, sputum conversion, conventional regimen
Abstract

Background Multi Drug Resistance (MDR) Tuberculosis (TB) is a global risk. Several suboptimal results were noticed which resulted to introduction of a standardised short regimen of 9-12 to optimise favourable outcomes. This new intervention has not been evaluated for effectiveness since inception in the Eastern Cape Province. Objective: To evaluate multidrug resistant tuberculosis conversion rate following initiation on short regimen.

Methods A retrospective study using a descriptive design was used to collect data from conveniently sampled 71 documents at Nkqubela TB and Duncan Village Day hospitals. Data were collected using a self-designed structured questionnaire and analysed using Statistical Packages for Social Sciences (SPSS) version 24.

Results Sixteen percent (n=19) of 71 records had no consecutive smear results. Demographic findings showed that the majority of the affected age group was between the ages of 36-45 years in both genders (34.7%, n=47) with males being highly affected more than females. The majority of participants were unemployed (51.7%), people living with HIV/AIDS (62.7%), use alcohol and smoking. Conversion rate was 68.5%.

Conclusion There is a need to review EDR web to accommodate sputum results irrespective of TB treatment start date. An extensive, ongoing counselling, support and health education needs to be provided for patients and families until the completion of treatment to emphasize the importance of monthly sputum collection and importance of treatment adherence. Clinicians need to strengthen their counselling and education skills. The introduction of short regimen to treat MDR has shown an improved sputum conversion rate in RR/MDR TB.

Introduction
Multidrug-resistant tuberculosis (MDR-TB) is defined as resistance to at least two key first-line drugs: isoniazid and rifampicin \[^1\]. This MDR-TB treatment is a lengthy regimen using mainly bacteriostatic which are too many, less effective, more toxic drugs, and thus is poorly tolerated by clients. Consequently, adherence is extremely difficult especially to infected clients who stay very far from the clinic and unemployed. Tuberculosis is an epidemic disease and it remains a global challenge. Tuberculosis is regarded as the tenth leading cause of death in the world, with estimated 580 000 new MDR cases \[^2\]. Africa is known to be carrying the greatest burden of TB and accounts for the largest proportion of TB/HIV cases worldwide \[^3,4\]. Patients diagnosed with RR/MDR-TB are treated for 18-24 months depending on the conversion date. Short regimen of 9-12 months was recommended in May 2016 \[^5\] and introduced in January 2017 in South Africa. The short regimen was recommended to shorten the time for TB treatment and to reduce lost to follow up clients on treatment. This study was conducted to examine RR/MDR-TB sputum outcomes after the introduction of a short regimen. Sputum conversion plays an important role in the management of tuberculosis because it determines response to TB treatment \[^6,7\]. Prognosis of the patient is determined by negativity or positivity of the sputum results. The overall duration for the current treatment regimen for MDR-TB is 20 months or more, requiring daily administration of drugs that are more toxic and less effective than those used to treat drug-susceptible TB and are costly \[^8,9\]. Unfavourable outcomes such as non-conversion of sputum culture are often produced at the end of intensive phase. Sputum conversion within the first two months serves as the predictor of treatment success in MDR TB patients. The chances of achieving treatment success or even sputum and culture conversion are largely suboptimal in MDR/XDRTB clients due to contributory factors. Factors such as use
of alcohol and smoking affect sputum conversion during management of MDR/XDR-TB

[10,11,12]. Therefore, with use of alcohol and smoking sputum conversion and good
response to treatment is less likely.

Therefore, this study was conducted to assess multidrug resistant tuberculosis conversion
rate following initiation of short regimen between January 2017 and July 2017.

Methodology

**Research design, setting and population**

A retrospective study was done using a quantitative descriptive design to extract data
from clients’ records who were diagnosed, registered and initiated on MDR TB treatment
between January 2017 and July 2017. The study was conducted at Nkqubela TB hospital
and Duncan Village Day Hospital both situated at Buffalo City Municipality Metropolitan.

Nkqubela TB Hospital is a centralised site and is regarded as the Centre of Excellence in
the management of drug resistant tuberculosis whereas Duncan Village Day Hospital is
one of the decentralised sites. Population comprised of all patient’s records diagnosed,
registered and initiated on multi-drug resistant TB treatment. A self-designed structured
questionnaire was used to extract information from conveniently sampled 71 records.

Inclusion criteria encompassed records of RR/MDR-TB participants who were registered
and initiated treatment at Nkqubela TB and Duncan Village Day Hospitals between the
period of January 2017 and July 2017.

**Inclusion and exclusion criteria**

The inclusion criteria encompassed RR/MDR TB participants who were registered and
initiated treatment for the first time at Nkqubela TB and Duncan Village Day Hospitals
between the period of 26 January 2017 and 31 July 2017. RR/MDR TB participants who are
12 years of age and older and those who have uncomplicated extra-pulmonary TB.
Exclusion criteria involved participants who were not registered and initiated RR/MDR-TB treatment at Nkqubela TB and Duncan Village Day Day Hospitals and those having complicated extra-pulmonary RR/MDR TB such as disseminated TB, TB of the abdomen.

**Data collection tool**

A self-made structured data extraction tool was used to extract secondary data from patient files. The instrument consisted of discrete and continuous data. Variables that were extracted were discrete, dichotomous, continuous, ordinal and nominal. Closed questions such as Yes or no and multiple choice questions. The tool entailed the following sections:

Section A: focuses on demographic data.

Section B: entails socio-economic data.

Section C: deals with medical and patient history.

Section D: consists of TB history and diagnosis.

Section E: focuses on TB treatment.

Section F: deals with sputum results and TB outcome.

**Validity and reliability**

The researcher conducted two different pilot studies. The first pilot study was done to 2 patient files and there were issues that needed to be addressed. After reconstructing the data extraction tool, a second pilot study was done to three patient files and it produced desirable results. Files used for pilot study were not used in the study. Two research assistants were trained on the data extraction tool for five working days. This enabled research assistants to understand the content of the tool and ask questions where possible. The same data extraction tool was used for the entire study to increase reliability. Secondary data that already existed in the patient files were used.

**ETHICAL CONSIDERATION**
Ethical approval was obtained from the University of Fort Hare Research Ethics Committee (Ethical Clearance Number MUP101SSOM01), Department of Health Research Ethics Committee, BCM Health District and two public hospitals.

**DATA ANALYSIS**

Unique codes were used to ensure anonymity. Data analysis was performed using SPSS version 24.0. MDRTB smear conversion were examined between January and July 2018 at the end of 12 months.

**Results**

All records of clients diagnosed and started treatment between January to July 2017 were retrieved for analysis. The ages of the participants were ranging between 14 and 89 years with mean age of 41 years, median of 40 years and a mode of 37 years. The age group of 36-45 years was the most affected (34.7%). Males (n=47) were more affected than females (n=24). The majority of affected racial group was the Africans with 98.3% of the participants. Many participants were from Buffalo City Metropolitan (52, 5%) with Bisho/KWT having high number of participants (27) in the district. Fifty two percent of the participants (n=61) were unemployed. Fifty-one records (72%) showed that the clients were HIV positive and 20 (28%) were HIV negative. Table 1 presents period at which participants had smear conversion.

| Data element                        | No. converted (%) |
|-------------------------------------|-------------------|
| Conversion rate in month 1-2        | 39 (33, 1%)       |
| Conversion rate in month 3-4        | 8 (5, 1%)         |
| Conversion rate in month 5-6        | 5 (2, 5%)         |
| No consecutive sputa                | 19 (16, 1%)       |
| Total                               | 71 (100%)         |

Table 1: Distribution of smear conversion

Out of 71 participants, 48 (68%) converted within month 1 and 6 of treatment. Nineteen participants (16, 1%) did not have consecutive sputa results during the intensive phase.
Discussion

Sputum conversion within the first two months serves as the predictor of treatment success in MDR-TB patients\(^6,\,13\). In the first 4 months of the treatment, conversion rate achieved was 38% and is sub-optimal. The factors that could have contributed to this low conversion rate were smoking and alcohol consumption especially in males\(^{14}\). Alcohol consumption and smoking have a negative effect in treatment adherence and reduce smear conversion rate at the correct time\(^{15,\,16}\).

Another contributory factor was unemployment, which was associated with non-adherence to treatment due to lack of transport fare to go to the clinic\(^{17,\,18}\).

According to medical history retrieved from patient files, 80% (n=94) of the participants had other comorbidities and 62, 7% were HIV positive. The mean viral load for all HIV positive participants was between 203183, 0 and 651888, 7 with mean CD4 count of 194, 5- 202, 4. The high number of HIV positive participants (n=74) proved the fact that a weakened immune system has a much greater risk of suffering from TB and if not on ART and the mortality rate ranges between 91 and 100%\(^{19,\,20,\,21}\). Poor HIV management increases the risk of getting infected with opportunistic infections. Data on comorbidities could not be obtained from two missing patient files.

There is a difference in monitoring TB treatment progress in conventional and short regimens. Conventional regimen is monitored by TB culture results whereas short regimen is monitored by TB smear results. TB culture results predict therapeutic efficacy in MDR-TB treatment as\(^6\) have alluded and in both conventional and short regimen TB culture determines TB treatment outcome. \(^6\) further state that sputum conversion within the first two months serves as the predictor of treatment success in MDR-TB patients. \(^{22}\)
states that the chances of achieving smear and culture conversion are largely suboptimal in MDR cases. The studies conducted by Damien Foundation on a short regimen over a period of 12 years showed that the short regimen achieved sputum culture negativity at the end of the intensive phase of 4 months \(^{5,23}\). Sputum smear conversion is a very important factor to predict treatment outcome \(^{24}\). Earlier conversion, especially in the first 3 months after initiation of treatment increases the likelihood of successful outcome.

In this study, out of 71 participants, 48 (68\%) converted within month one and six of treatment, which is a positive predictor that these clients will be cured at 9 months. Smear conversion rate of 68.5\% despite contributory factors mentioned by \(^{6}\) have made a great predictor of treatment outcome. Therefore, clients on TB treatment need to be educated on use of alcohol and smoking. Clinicians need to strengthen their counselling skills regarding education of the clients on admission. The number of participants who converted might have increased if all participants complied with monthly sputum collection as indicated by Department of Health (2018), out of 19 participants who had no consecutive smear results, 6 of them had a positive outcome \(^{25,26}\). Therefore, clients need to be educated about the importance of monthly producing of sputum for early prediction of the outcome.

**Conclusions And Implications For Health Policy**

Standardised short regimen for treatment MDRTB has shown promising and positive results. The results of the study has shown high success rate if adhered to the guidelines. Conversion rate can be affected by many factors including and not limited to alcohol use, smoking and non-producing of smear when needed for testing. There is a need to review EDR web to accommodate sputum results irrespective of TB treatment start date. An extensive, ongoing counselling, support and health education needs to be provided to
patients and families until the completion of treatment to emphasize the importance of monthly sputum collection, duration of treatment, reporting of adverse drug effects and importance of treatment adherence. Clinicians need to strengthen their counselling and education skills to ensure that the clients are well informed. The introduction of short regimen to treat MDR has shown an improved sputum smear conversion rate in RR/MDR TB.

Limitations Of The Study

The researcher was unable to assess perceptions and experiences of the participants due the quantitative method used. Only two institutions that register and initiate drug resistant TB treatment were studied, therefore generalizability will be limited to BCM. The study could not enrol many participants due to time constraints and the duration of treatment the participants had to take.

Declarations

Acknowledgement

The Eastern Cape Department of Health, Buffalo City Metropolitan Health District, Nkubela TB Hospital, and Duncan Village Day Hospital are highly appreciated for concerning this study to be conducted.

CONFLICT OF INTEREST

The authors declare that they have no competing interest, financial or otherwise

Author Contributions

NS carried out the design, data collection, participated in data analysis and drafted the manuscript. WM and NGM participated in data analysis and helped to draft the manuscript. All authors read and approved the final manuscript.

Funding sources
No funding was received from any institution to carry out this study

References

[1] Gadallah, M.A., Mokhtar, A., Rady, M., El-Moghazy, E., Fawzy, M. and Kandil, S.K., 2016. Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt. *Journal of the Formosan Medical Association, 115*(11), pp.997-1003.

[2] World Health Organization, 2018. Compendium of WHO guidelines and associated standards: ensuring optimum delivery of the cascade of care for patients with tuberculosis.

[3] Sulis, G., Centis, R., Sotgiu, G., D’Ambrosio, L., Pontali, E., Spanevello, A., Matteelli, A., Zumla, A. and Migliori, G.B., 2016. Recent developments in the diagnosis and management of tuberculosis. *NPJ primary care respiratory medicine, 26*(1), pp.1-8.

[4] Bouti, K., Aharmim, M., Marc, K., Soualhi, M., Zahraoui, R., Benamor, J., Bourkadi, J.E. and Iraqi, G., 2013. Factors influencing sputum conversion among smear-positive pulmonary tuberculosis patients in Morocco. *ISRN pulmonology, 2013*.

[5] World Health Organization, 2016. *The shorter MDR-TB regimen features of the shorter MDR-TB regimen*, World Health Organization. Available at: http://www.who.int/tb/Short_MDR_regimen_factsheet.pdf.

[6] Liu, Q., Lu, P., Martinez, L., Yang, H., Lu, W., Ding, X. and Zhu, L., 2018. Factors affecting time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis in China. *BMC infectious diseases, 18*(1), p.114.

[7] Kurbatova, E.V., Cegielski, J.P., Lienhardt, C., Akksilp, R., Bayona, J., et al., 2015. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two
observational cohort studies. *The Lancet Respiratory medicine, 3*(3), pp.201-209.

[8] World Health Organization, 2013. *The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance* (No. WHO/HTM/TB/2013.6). World Health Organization.

[9] Schnippel, K., Rosen, S., Shearer, K., Martinson, N., Long, L., Sanne, I. and Variava, E., 2013. Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa. *Tropical Medicine & International Health, 18*(1), pp.109-116.

[10] Marahatta, S.B., 2010. Multi-drug resistant tuberculosis burden and risk factors: an update. *Kathmandu University medical journal, 8*(1), pp.116-125.

[11] Pefura-Yone, E.W., Kengne, A.P., Kuaban, C., 2014. Non-conversion of sputum culture among patients with smear positive pulmonary tuberculosis in Cameroon: A prospective cohort study. *BMC Infectious Diseases 14*. doi:10.1186/1471-2334-14-138

[12] Velayutham, B., Nair, D., Kannan, T., Padmapriyadarsini, C., Sachdeva, K.S., Bency, J., Klinton, J.S., Haldar, S., Khanna, A., Jayasankar, S. and Swaminathan, S., 2016. Factors associated with sputum culture conversion in multidrug-resistant pulmonary tuberculosis. *The International Journal of Tuberculosis and Lung Disease, 20*(12), pp.1671-1676.

[13] Ige, O.M., Oladokun, R.E., 2018. Time to sputum culture conversion and treatment outcome among the first cohort of multidrug resistant tuberculosis patients in a high burden country. *Indian Journal of Tuberculosis 65*, 322–328. doi:10.1016/j.iijtb.2018.07.006

[14] Ndwandwe, Z. S., Mahomed, S., Lutge, E., & Knight, S. E. (2014). Factors affecting non-adherence to tuberculosis treatment in uMgungundlovu Health District in 2010. *Southern African Journal of Infectious Diseases, 29*(2), 56-59.

[15] de Boer, R.N., e Souza, J.B.D.O., Cobelens, F., de Paula Ramalho, D., Miranda, P.F.C.,
de Logo, K., Oliveira, H., Mesquita, E., Oliveira, M.M. and Kritski, A., 2014. Delayed culture conversion due to cigarette smoking in active pulmonary tuberculosis patients. *Tuberculosis, 94*(1), pp.87-91.

[16] Qazi, F., Khan, U., Khowaja, S., Javaid, M., Ahmed, A., Salahuddin, N., Hussain, H., Becerra, M.C., Golub, J.E. and Khan, A.J., 2011. Predictors of delayed culture conversion in patients treated for multidrug-resistant tuberculosis in Pakistan. The International journal of tuberculosis and lung disease, 15(11), pp.1556-1560.

[17] World Health Organization, 2014. *Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis*. Switzerland: WHO Library Cataloguing-in-Publication Data. 9-167.

[18] Javaid, A., Shaheen, Z., Shafqat, M., Khan, A.H. and Ahmad, N., 2017. Risk factors for high death and loss-to-follow-up rates among patients with multidrug-resistant tuberculosis at a programmatic management unit. *American journal of infection control, 45*(2), pp.190-193.

[19] World Health Organization, 2015. *Guide to Monitoring and Evaluation for Collaborative TB/HIV Activities--2015 Update*. World Health Organization.

[20] Adeiza, M., Okpapi, J., Abba, A., 2014. HIV-Associated tuberculosis: A Sub-Saharan African perspective. Sub-Saharan African Journal of Medicine 1, 1. doi:10.4103/2384-5147.129299

[21] Brust, J.C., Lygizos, M., Chaiyachati, K., Scott, M., van der Merwe, T.L., Moll, A.P., Li, X., Loveday, M., Bamber, S.A., Lalloo, U.G. and Friedland, G.H., 2011. Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa. *PloS one, 6*(1).

[22] Chuang, P.H., Wu, M.H., Fan, S.Y., Lin, K.Y. and Jou, R., 2016. Population-based drug
resistance surveillance of multidrug-resistant tuberculosis in Taiwan, 2007-2014. *PloS one*, 11(11), p.e0165222

[23] Moodley, R., & Godec, T. R. (2016). Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. *European Respiratory Review, 25*(139), 29-35

[24] Basit, A., Ahmad, N., Khan, A.H., Javaid, A., Sulaiman, S.A.S., Afridi, A.K., Adnan, A.S., ul Haq, I., Shah, S.S., Ahadi, A. and Ahmad, I., 2014. Predictors of two months culture conversion in multidrug-resistant tuberculosis: findings from a retrospective cohort study. *PloS one, 9*(4).

[25] Kweza, P.F., Van Schalkwyk, C., Abraham, N., Uys, M., Claassens, M.M. and Medina-Marino, A., 2018. Estimating the magnitude of pulmonary tuberculosis patients missed by primary health care clinics in South Africa. *The International Journal of Tuberculosis and Lung Disease, 22*(3), pp.264-272.

[26] Sharma, S.K. and Mohan, A., 2013. Tuberculosis: From an incurable scourge to a curable disease-journey over a millennium. *The Indian journal of medical research, 137*(3), p.455.